Gadoteric Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Gadoteric Acid: From MRI Contrast Agent to Osteoarthritis
One-Sentence Summary
Gadoteric acid (Gd-DOTA) is a macrocyclic gadolinium-based MRI contrast agent used intravenously to enhance magnetic resonance imaging in various diagnostic contexts. The TxGNN model predicts it may be effective for Osteoarthritis, however this prediction is most likely a diagnostic co-occurrence false signal — the drug is widely used to image osteoarthritic joints (via the dGEMRIC technique), and the model may have learned this diagnostic association as a therapeutic one. There are currently 0 clinical trials and 0 publications supporting a therapeutic role in osteoarthritis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | MRI contrast enhancement (no Singapore regulatory data available) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.57% |
| Evidence Level | L5 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on well-established knowledge, Gadoteric acid (brand name: Dotarem) is a macrocyclic, ionic, gadolinium-chelate contrast agent. It functions by shortening the T1 relaxation time of protons in surrounding tissues, thereby enhancing signal intensity on T1-weighted MRI sequences. It has no known pharmacodynamic effect on any tissue — it is purely a diagnostic tool.
The link between gadoteric acid and osteoarthritis almost certainly reflects a diagnostic co-occurrence artefact. Gd-DOTA is used in the dGEMRIC (delayed Gadolinium-Enhanced MRI of Cartilage) technique to evaluate glycosaminoglycan content in articular cartilage, enabling non-invasive assessment of osteoarthritic joint damage. The TxGNN knowledge graph contains associations between Gd-DOTA and osteoarthritis because the agent is used to diagnose and monitor the disease — not to treat it.
This same pattern recurs across all top-10 predictions in this Evidence Pack: the drug appears alongside musculoskeletal diseases (osteoarthritis, rheumatoid arthritis, gout, skeletal dysplasias) in the medical literature and clinical databases exclusively in a diagnostic imaging context. There is no known mechanism by which an extracellular gadolinium chelate could modify disease biology in any of these conditions. The prediction score reflects diagnostic co-occurrence, not therapeutic potential.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the osteoarthritis indication.
Note on rank-3 indication (Rheumatoid Arthritis): Two publications were retrieved — PMID 1727317 (Radiology, 1992) and PMID 2115261 (AJR, 1990) — both classified as Diagnostic Imaging Studies. They document Gd-DOTA uptake in inflamed synovium as a marker of disease activity, not as a treatment. These publications reinforce rather than contradict the false-signal interpretation.
Singapore Market Information
Gadoteric acid is not registered in Singapore. No product authorisations are on file.
Safety Considerations
Please refer to the package insert for safety information.
Specific caution flagged by the Evidence Pack: For the hepatic porphyria prediction (rank 5), the mechanistic rationale notes that heavy metal chelates may potentially trigger a porphyric crisis. While this is not directly relevant to the top osteoarthritis prediction, it should be documented as a background safety signal if any exploratory use is ever considered.
Conclusion and Next Steps
Decision: Hold
Rationale: All 10 TxGNN-predicted indications for gadoteric acid share the same fundamental problem: the drug is a passive diagnostic contrast agent with no pharmacodynamic activity on disease biology. The high prediction scores (98.57%–97.38% across all ranks) represent a systematic diagnostic co-occurrence false signal — the model has learned that gadolinium MRI is used alongside these diseases, and incorrectly interpreted this as a therapeutic relationship. No clinical trials or supportive therapeutic literature exist for any predicted indication.
To proceed, the following is needed:
- Do not pursue further repurposing evaluation without a credible mechanistic hypothesis that is independent of diagnostic imaging use
- Conduct a formal false-positive signal review: confirm whether the TxGNN knowledge graph encodes diagnostic imaging relationships separately from therapeutic relationships; if not, all gadolinium-based contrast agents in the dataset should be flagged as a class
- If MRI-guided drug delivery applications are of interest (a genuinely distinct research area), a separate evidence pack with focused literature search on theranostic gadolinium platforms would be required — this is a different question from standard repurposing
- Singapore regulatory pathway is moot at this stage given zero market presence and no therapeutic evidence base
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.